AstraZeneca’s (AZN) Buy Rating Reiterated at Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Berenberg Bank in a report released on Wednesday,London Stock Exchange reports. They presently have a GBX 140 ($1.80) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential downside of 98.75% from the company’s previous close.

Several other research analysts have also recently commented on the company. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of GBX 7,542.80 ($97.11).

AstraZeneca Trading Down 0.1 %

AZN stock traded down GBX 8 ($0.10) during midday trading on Wednesday, hitting £112.24 ($144.51). 16,843,158 shares of the company’s stock were exchanged, compared to its average volume of 23,815,439. AstraZeneca has a 1-year low of GBX 9,670 ($124.50) and a 1-year high of £133.88 ($172.37). The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market capitalization of £215.95 billion, a PE ratio of 30.77, a P/E/G ratio of 0.86 and a beta of 0.17. The business has a 50-day simple moving average of £115.70 and a two-hundred day simple moving average of £112.80.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.